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Summary
Background.  —  In  patients  with  myotonic  dystrophy  type  1  (DM1),  the  mechanisms  underlying
sudden cardiac  death,  which  occurs  in  up  to  1/3  of  patients,  are  unclear.
Abbreviations: cDNA, complementary deoxyribonucleic acid; DM1, dystrophia myotonica type 1; DMPK, dystrophia myotonica protein
kinase; DNA, deoxyribonucleic acid; ECG, electrocardiogram; mRNA, messenger ribonucleic acid; PCR, polymerase chain reaction; RNA,
ribonucleic acid; SD, standard deviation; RT, reverse transcriptase.
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Aims.  —  To  study  the  potential  role  of  Brugada  syndrome  in  ventricular  tachyarrhythmias  and
sudden death  in  DM1  patients.
Methods.  —  We  screened  914  adult  patients  included  in  the  DM1  Heart  Registry  during
2000—2009 for  the  presence  of  type  1  Brugada  pattern  on  electrocardiogram  (ECG).  We  also
performed  direct  sequencing  of  SCN5A  in  patients  with  Brugada  pattern.  Further,  we  analysed
SCN5A splicing  on  ventricular  myocardial  specimens  harvested  during  cardiac  transplantation
in a  45-year-old  patient  with  DM1  and  three  controls  with  inherited  dilated  cardiomyopathy.
Results.  —  A  type  1  Brugada  pattern  was  present  on  the  ECG  of  seven  of  914  patients  (0.8%),
including ﬁve  with  a  history  of  sustained  ventricular  tachyarrhythmia  or  sudden  death,  who
fulﬁlled the  criteria  for  Brugada  syndrome.  SCN5A  sequencing  was  normal  in  all  patients.  Ventri-
cular myocardial  specimen  analysis  displayed  abnormal  splicing  of  SCN5A  exon  6,  characterized
by over-expression  of  the  ‘neonatal’  isoform,  called  exon  6A,  in  the  patient  with  DM1,  but  not
from the  controls.
Conclusion.  —  Our  ﬁndings  suggest  a  potential  implication  of  Brugada  syndrome  in  sudden  death
in DM1,  which  may  be  related  to  missplicing  of  SCN5A.  Our  ﬁndings  provide  a  new  insight  into
the pathophysiology  of  heart  disease  in  DM1.
ClinicalTrials.gov.  —  Number  NCT01136330.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Dans  la  dystrophie  myotonique  de  type  1  (DM1),  les  mécanismes  de  la  mort  subite,
qui sont  responsables  d’un  tiers  des  décès,  sont  inconnus.
Objectif.  —  Étudier  l’implication  du  syndrome  de  Brugada  dans  les  troubles  du  rythme  ventric-
ulaires et  la  mort  subite  dans  la  DM1.
Méthodes.  —  Nous  avons  recherché  un  aspect  de  Brugada  de  type  1  sur  les  électrocardiogrammes
de 914  patients  adultes  inclus  dans  le  DM1  Heart  Registry  entre  2000  et  2009.  Un  séquenc¸age
direct de  SCN5A  a  été  effectué  chez  les  porteurs  d’un  Brugada  de  type  1.  Nous  avons  étudié
l’épissage de  SCN5A  sur  du  tissu  myocardique  prélevé  lors  de  transplantations  cardiaques  chez
un patient  atteint  de  DM1  et  trois  témoins  atteints  de  cardiomyopathies  dilatées.
Résultats.  — Un  aspect  de  Brugada  de  type  1  a  été  identiﬁé  chez  sept  patients  (0,8  %),  dont
cinq remplissant  les  critères  pour  un  diagnostic  de  syndrome  de  Brugada,  devant  l’association  à
un trouble  du  rythme  ventriculaire  soutenu  ou  une  mort  subite.  Le  séquenc¸age  de  SCN5A  était
normal chez  tous  ces  patients.  L’étude  du  tissu  myocarde  du  patient  DM1  a  mis  en  évidence  un
épissage anormal  de  l’exon  6  de  SCN5A,  caractérisé  par  la  surexpression  de  l’isoforme  6A,  dite
isoforme « néonatale  »,  non  identiﬁée  dans  les  tissus  témoins.
Conclusions.  — Ces  résultats  suggèrent  l’implication  potentielle  du  syndrome  de  Brugada  dans
certains cas  de  mort  subite  chez  les  patients  atteints  de  DM1,  qui  pourrait  être  liée  à  des
anomalies d’épissage  de  SCN5A.  De  manière  plus  générale,  ces  résultats  apportent  un  éclairage
nouveau sur  la  physiopathologie  de  l’atteinte  cardiaque  dans  cette  pathologie.
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yotonic  dystrophy  type  1  (DM1),  also  known  as  Steinert  dis-
ase,  is  the  most  common  inherited  neuromuscular  disease
n  adults  with  an  incidence  of  1/8000  [1]. It  is  an  autosomal
ominant  disorder  mapping  to  chromosome  19q,  caused  by
n  expansion  of  a  (CTG)n  triplet  repeat  in  the  3’  region  of  the
ene  encoding  dystrophia  myotonica  protein  kinase  (DMPK)
2].
The  main  pathogenetic  characteristic  of  DM1  is  the
uclear  accumulation  of  mutant  messenger  ribonucleic
cids  (mRNAs),  which  induces  the  aberrant  alternative
plicing  of  multiple  pre-mRNAs  responsible  for  pheno-
ypical  abnormalities  of  multiple  systems  [3,4].  Clinical
anifestations  of  DM1  include  myotonia,  progressive  skele-
al  muscle  loss,  cataracts,  insulin  resistance  and  heart
isease.
[
ts  droits  réservés.
The  most  frequent  cardiac  complications  of  DM1  are
trioventricular  block,  sinus  node  dysfunction,  atrial  ﬁbril-
ation  and  ventricular  tachyarrhythmias  [5—8].  Up  to  1/3
f  DM1  patients  die  suddenly,  most  often  due  to  asystole
fter  atrioventricular  block  or  from  ventricular  ﬁbrillation
9,10].  Severe  ECG  conductive  abnormalities  or  a  diagnosis
f  atrial  tachyarrhythmia  predict  sudden  death  [11].  Pro-
hylactic  pacing  has  been  associated  with  improved  survival
12], but  indications  for  the  implantation  of  a  cardioverter
eﬁbrillator  are  not  clear,  as  clinical  risk  factors  speciﬁc
o  ventricular  arrhythmias  have  not  yet  been  identiﬁed.
n  addition,  in  contrast  with  other  manifestations  of  the
isease  [13,14], the  mechanisms  behind  the  development
f  cardiac  arrhythmias  have  not  been  clearly  identiﬁed
15—18].
Brugada  syndrome  is  an  autosomal  dominant  disorder
hat  associates  ST-segment  elevation  in  leads  V1  to  V3  on  the
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TMyotonic  dystrophy  and  Brugada  syndrome  
electrocardiogram  (ECG)  and  a  high  incidence  of  ventricular
ﬁbrillation  and  sudden  cardiac  death  [19].  SCN5A,  the  gene
encoding  the  Na+  channel  -subunit  expressed  in  the  human
heart,  is  the  main  gene  responsible  for  this  syndrome  [20].
Other  cardiac  manifestations  of  SCN5A  mutations  causing
Na+  channel  loss  of  function,  such  as  familial  atrioventricu-
lar  blocks  or  atrial  ﬁbrillation  [21],  are  very  similar  to  those
observed  in  DM1.
We  tested  the  hypothesis  that  Brugada  syndrome
could  be  a  cause  of  severe  ventricular  arrhythmias  in
DM1.  We  therefore  assessed  the  prevalence  of  patients
with  a  Brugada  ECG  pattern  in  a  large  population  of
DM1  patients  and  their  risk  proﬁle  for  severe  ventri-
cular  arrhythmias  and  studied  the  splicing  of  SCN5A  in
myocardial  tissue  harvested  from  a  patient  suffering  from
DM1.
Methods
Screening for type 1 Brugada ECG pattern
among patients included in the DM1 Heart
Registry
We  screened  for  the  presence  of  a  Brugada  pattern  on
the  ECGs  of  patients  included  in  the  DM1  Heart  Reg-
istry.  This  Registry  was  designed  and  organized  by  the
Neurological  Unit  of  Pitié-Salpêtrière  Hospital  and  the  Car-
diological  Unit  of  Cochin  Hospital  (ClinicalTrials.gov  no:
NCT01136330).  This  registry  retrospectively  included  914
consecutive  patients  aged  ≥  18  years  admitted  to  our
institutions  between  January  2000  and  December  2009  for
the  management  of  DM1,  diagnosed  by  the  presence  of
≥  50  CTG  triplets  in  the  3’  un-translated  region  of  the
DMPK  gene  of  blood  leukocytes.  The  patients’  medical
records  were  reviewed  and  the  genetic,  neurological  and
cardiac  information  was  entered  in  a  dedicated  database.
The  patients’  ECGs  at  baseline  and  during  follow-up  were
screened  for  type  1  Brugada  pattern  [22]  by  two  inde-
pendent  experts  (HMB  and  DD)  who  were  unaware  of  the
patients’  information.  A  Brugada  pattern  was  considered  to
be  present  when  both  investigators  shared  the  same  positive
interpretation.
This  study,  which  complies  with  the  ethical  principles  for-
mulated  in  the  declaration  of  Helsinki,  was  approved  by  our
local  ethics  committee,  and  all  patients,  except  those  who
died  before  initiation  of  the  study,  granted  their  informed
written  consent  to  participate  in  the  registry.
Cardiac investigations
Patients  with  type  1  Brugada  pattern  underwent  clini-
cal  examination,  12-lead  ECG,  24-hour  ambulatory  ECG,
echocardiography  and  electrophysiological  testing.  The
electrophysiological  testing  protocol  used  one  bipolar  and
one  quadripolar  electrode  introduced  into  the  femoral  vein
and  advanced  to  the  right  atrium  and  right  ventricle,  respec-
tively.  Programmed  stimulation  was  performed  with  three
extrastimuli  at  a  strength  equal  to  twice  end-diastolic
threshold  delivered  during  spontaneous  rhythm  and  after
paced  trains  at  rates  of  100  and  150  bpm  from  the  high
B
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ight  atrium  and  from  right  ventricular  apex  and  pulmonary
utﬂow  tract.
CN5A sequencing in patients with type 1
rugada pattern
he  patients  whose  ECG  was  consistent  with  type  1  Brugada
attern  underwent  direct  sequencing  of  SCN5A  on  genomic
eoxyribonucleic  acid  (DNA)  from  blood  lymphocytes.  All
oding  exons  and  intronic  ﬂanking  sequences  were  ampliﬁed
y  polymerase  chain  reaction  (PCR)  as  previously  described
23].
tatistical analysis
ata  are  expressed  as  mean  ±  standard  deviation  (SD)  for
ontinuous  variables,  and  counts  and  percentages  for  cate-
orical  variables.  The  STATA® statistical  software,  version
0.1  (StataCorp  LP,  College  Station,  TX)  was  used  for  all
nalyses.
ibonucleic acid (RNA) splicing studies in
uman ventricular myocardial tissue
entricular  myocardial  specimens  were  harvested  during
ardiac  transplantation  for  end  stage  heart  failure  in:  (1)
 45-year-old  patient  suffering  from  DM1  (166  CTG  repeats)
nd  dilated  cardiomyopathy  with  conduction  system  disease
nd  (2)  three  control  patients  suffering  from  familial  dilated
ardiomyopathy  of  uncharacterized  genetic  origin.  Total
NA  was  extracted  using  the  kit  RNAPLUS2TM  according  to
anufacturer’s  instructions  corresponding  to  an  improve-
ent  on  Chomczynski’s  procedure  [24].  We  used  a  reverse
ranscriptase  (RT)-PCR  assay  to  study  the  alternative  splic-
ng  in  right  ventricular  myocardial  tissue  of  SCN5A  and  two
ontrol  genes  where  abnormal  splicing  has  previously  been
eported  in  DM1:  troponin  T  and  dystrophin  [25,26].  For  the
CN5A  splicing  study,  a  set  of  primers  spanning  all  the  genes
ere  selected.  PCR  was  performed  using  the  GeneAmp®
CR  System  9700  (Applied  Biosystems,  France).  Products
ere  analysed  by  Gel  Electrophoresis  to  detect  abnormal
plicing.  PCR  products  were  sequenced  using  the  ‘‘BigDye®
erminator  v.3.1  cycle  sequencing  kit’’  on  ABI  PRISM  3130
nalyser  (Applied  Biosystems).  Primers  sequences,  with  their
osition  on  the  complementary  DNA  (cDNA)  variant  Nav1.5
NM  000335),  and  technical  conditions  are  available  on
equest.  PCR  products  were  subjected  to  restriction  anal-
sis  with  Bfa  I  and  ApoI,  respectively,  speciﬁc  to  digestion  of
xons  6a  and  6b  of  SCN5A.  The  digestion  protocol  was  carried
ut  in  appropriate  reaction  buffer  NEB  3  with  BSA  (100  mM
aCl;  50  mM  Tris-HCl;  pH:  7.9;  10  mM  MgCl2  SH:  1  mM  DTT;
SA:  100x).  The  resulting  fragments  were  analysed  by  elec-
rophoresis.
esults
he DM1 Heart Registry: prevalence of type 1
rugada pattern
he  baseline  characteristics  of  the  914  patients  included
n  the  DM1  Heart  Registry  are  summarized  in  Table  1.
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Table  1  Baseline  characteristics  of  patients  entered  in  the  DM1  Heart  Registry.
All  patients  (n  =  914)
Age  (years)  38  ±  14
Men  443  (48.5)
Heart  rate  (bpm)  69  ±  13
Systolic  blood  pressure  (mmHg)  117  ±  13
Diastolic  blood  pressure  (mmHg)  67  ±  9
Cytosine-thymine-guanine  ampliﬁcation  size  (number  of  triplets)  604  ±  415
History  of
Supraventricular  arrhythmia 64  (7.0)
Complete  heart  block  4  (0.4)
Sinus  node  dysfunction  12  (1.3)
Sustained  ventricular  tachyarrhythmia  3  (0.3)
Pacemaker  implantation  67  (7.3)
Cardioverter  deﬁbrillator  implantation 3  (0.3)
Surface  and  intracardiac  ECG  observations
First  degree  atrioventricular  block  287  (31.4)
Bundle  branch  block
Left  98  (10.7)
Right  63  (6.9)
Paced  rhythm  23  (2.5)
Brugada  pattern  7  (0.8)
Intervals  (ms)
PR  189  ±  31
QRS  100  ±  19
Corrected  QT  410  ±  29
AHa 117  ±  47
Ha 18  ±  5
HVa 66  ±  12
HV  interval  >  55  ms  and  <  70  msa 115  (46.4)
HV  interval  ≥  70  msa 96  (38.7)
Induced  ventricular  ﬁbrillation  or  sustained  polymorphic  ventricular  tachycardiaa 21  (8.5)
Echocardiographic  measurementsb
Left  ventricular
Dysfunction  50  (5.6)
End-diastolic  diameter  (mm/m2)  45  ±  5
Posterior  wall  thickness  (mm)  7.8  ±  1.4
Mass  (g)  204  ±  61
Ejection  fraction  (%)  63  ±  7
Septal  wall  thickness  (mm)  8.6  ±  1.7
Device  therapy  at  inclusion  in  the  Registry
Pacemaker  66  (7.2)
Implantable  cardioverter  deﬁbrillator  8  (0.9)
Data are means ± SD or range, or number (%); DM: dystrophia myotonica; ECG: electrocardiogram; SD: standard deviation.
a n = 248.
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onduction  system  disease  was  present  in  376  patients
41.1%),  a  history  of  supraventricular  arrhythmia  in  64
7.0%),  left  ventricular  dysfunction  in  50  (5.6%),  and  sus-
ained  ventricular  tachyarrhythmia  in  three  patients  (0.3%).
 type  1  Brugada  pattern  (Fig.  1)  was  present  on  the  12-
ead  ECG  of  seven  patients  (0.8%),  whose  characteristics
re  summarized  in  Table  2.  No  patient  had  a  family  history
s
p
i
1f  sudden  death  or  Brugada  syndrome.  The  ECG  Brugada
attern  was  intermittent  in  three  patients,  without  appar-
nt  trigger.  Programmed  ventricular  stimulation  induced
ustained  ventricular  tachyarrhythmia  in  four  patients,
rompting  the  implantation  of  a  cardioverter  deﬁbrillator
n  three  patients  and  a  pacemaker  in  one  patient  (no.
),  who  had  refused  to  undergo  the  implantation  of  a
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Table  2 Characteristics  of  the  seven  patients  presenting  with  DM1  and  Brugada  ECG  pattern.
Patient  no. 1  2  3  4  5  6  7
Sex  Male  Male  Male  Female  Male  Male  Male
Age  (years) 54  44  43  39  33  39  40
CTG  ampliﬁcation  size  of  DM1  mutation 200 150  670  660  200  467  1100
Symptoms  —  Light-headedness  —  —  —  —  Palpitations
ECG  intervals  (ms)
PR  200  240  230  250  183  194  172
QRS  110  130  122  125  106  105  110
Corrected  QT 420  425  378  430  392  415  380
24-hour  ambulatory  ECG AF AF  Normal  Normal  Normal  Normal  Normal
Echocardiographic  measurements
Left  ventricular
End-diastolic  diameter  index  (mm/m2)  25.9  25.0  24.9  27.0  27.5  19.7  30.4
Posterior  wall  thickness  (mm)  7  9  10  6  8  6  8
Mass  index  (g/m2) 78  78  78  59  80  34  98
Ejection  fraction  (%) 63  65  68  63  63  60  65
Septal  wall  thickness  (mm) 11  9  10  9  9  7  10
Electrophysiological  observations
Intervals  (ms)
AH  125  110  90  100  —  116  105
H  20  18  20  20  —  25  20
HV  74  56  55  90  —  58  55
Induced  tachyarrhythmia  PVT  VF  PVT  —  —  —  PVT
Long-term  observations
Oral  medications  BB  Aspirin  None  —  —  —  BB
Device  implantation  (age  [years])  Pacemaker  (56)  ICD  (51)  ICD  (51)  Pacemaker  (41)  None  —  ICD  (44)
Major  adverse  event  (age  [years])  Sudden  death  (57)  None  —  —  Sudden  death  (37)  —  —
AF: atrial ﬁbrillation; BB: beta-blocker; CTG: cytosine-thymine-guanine; DM1: dystrophia myotonica type 1; ECG: electrocardiogram; ICD: implantable cardioverter deﬁbrillator; PVT:
polymorphic ventricular tachycardia; VF: ventricular ﬁbrillation.
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Bigure 1. Screened surface ECGs from the DM1 Heart Registry. Sp
f seven patients with DM1. The typical abnormalities included a ≥
he V1 and V2 (arrows) precordial leads. DM1: dystrophia myotonic
eﬁbrillator  and  who  died  suddenly  of  ventricular  ﬁbrilla-
ion.  Patient  no.  6  also  died  suddenly,  though  no  ECG  was
ecorded  at  the  time  of  death.  Overall,  ﬁve  of  the  seven
atients  had  a  history  of  sustained  ventricular  tachyarrhyth-
ia  or  died  suddenly,  fulﬁlling  the  criteria  for  Brugada
yndrome.
T
w
sneous type 1 Brugada patterns were identiﬁed on the 12-lead ECGs
V coved ST-segment elevation, followed by a negative T wave in
e 1; ECG: electrocardiogram.
CN5A sequencing in patients with type 1
rugada patternhe  SCN5A  sequence,  analysed  in  six  of  the  seven  patients,
as  normal.  It  was  not  analysed  in  patient  no.  1,  who  died
uddenly  before  undergoing  genetic  testing.
Myotonic  dystrophy  and  Brugada  syndrome  
Figure 2. Gel electrophoresis of RT-PCR products from right ven-
tricular myocardial tissue of the patient suffering from DM1 versus
controls. Red arrows indicate abnormal splicing of DMD and TNNT2.
C: control; DM1: dystrophia myotonica type 1; RT-PCR: reverse
transcriptase polymerase chain reaction.
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tRNA splicing in human ventricular myocardial
tissue
Splicing  abnormalities  of  dystrophin  (exon  78)  and  troponin
T  (exon  5)  were  identiﬁed  by  RT-PCR  in  ventricular  myocar-
dial  specimens  obtained  from  the  tested  patient  suffering
from  DM1,  though  not  from  the  controls  (Fig.  2).  SCN5A
sequencing  displayed  abnormal  splicing  of  exon  6 with  the
expression  of  an  isoform  differing  from  the  normal  one  at  31
of  its  92  nucleotides,  which  has  been  previously  reported  as
‘neonatal’  exon  6,  also  called  exon  6A  or  6a  [27].  Restriction
analysis  with  Bfa  I  (Fig.  3A)  showed  signiﬁcant  expression
of  the  6A  isoform  in  the  patient  with  DM1  but  not  in  the
controls.  Restriction  analysis  with  ApoI  (Fig.  3B)  showed
reduced  expression  of  exon  6b,  which  was  normal  in  the
controls.
D
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Figure 3. Restriction analysis of SCN5A exon 6 RT-PCR products from r
versus controls (C1—C3). Digestion by Bfa I (A) (red arrows indicate SCN5A
SCN5A exon 6 isoforms, which were not digested and absent in the contro
transcriptase polymerase chain reaction.641
iscussion
ur  study  is  the  ﬁrst  to  report  an  association  between  DM1
nd  Brugada  ECG  pattern  and  cardiac  abnormal  splicing  of
CN5A  in  a  DM1  patient.
The  prevalence  of  spontaneous  type  1  Brugada  ECG
attern  in  our  DM1  patients  was  7.7/1000.  While  this  preva-
ence  is  low  compared  with  other  disease  manifestations  of
M1,  it  is  nearly  50-fold  higher  than  the  0.17/1000  preva-
ence  observed  in  apparently  healthy  European  populations
28,29].  Furthermore,  this  prevalence  might  be  underes-
imated,  because:  (1)  major  intraventricular  conduction
isorders  or  paced  QRS  complexes  might  have  concealed  a
ypical  Brugada  pattern  [30]  and  (2)  no  class  I  antiarrhythmic
ests  were  performed  to  unmask  a  latent  Brugada  pattern
ecause  one  DM1  patient  died  of  a  ventricular  tachycardia
torm  after  an  ajmaline  infusion  during  electrophysiologi-
al  testing  in  one  of  our  previous  studies  [31]. We  assume
hat  previous  studies  describing  cardiac  involvement  in  DM1
robably  did  not  identify  the  high  prevalence  of  type  1  Bru-
ada  pattern  in  DM1  patients  because  procedures  for  ECG
nalysis  were  not  standardized  or  the  population  sizes  were
oo  small.
Our  clinical  ﬁndings  have  implications  for  patient  man-
gement  as,  among  our  seven  DM1  patients  with  a  type
 Brugada  pattern,  two  died  suddenly  (including  one  due
o  a  ventricular  ﬁbrillation  despite  the  implantation  of
 pacemaker)  and  three  had  a positive  ventricular  pro-
rammed  stimulation.  The  prognostic  value  of  programmed
entricular  stimulation  in  patients  with  Brugada  pattern  is
ontroversial.  However,  we  believe  that  the  identiﬁcation  of
 Brugada  pattern  in  DM1  patients  should  be  considered  as  a
ajor  risk  factor  for  ventricular  arrhythmias.  Therefore,  the
mplantation  of  a  cardiac  deﬁbrillator  should  be  discussed  in
hese  patients.  In  particular,  patients  for  whom  a  pacemaker
s  indicated  for  conductive  disease  could  beneﬁt  from  a  car-
iac  deﬁbrillator  rather  than  a  pacemaker.  This  fairly  high
isk  for  ventricular  arrhythmias  may  have  several  explana-
ions,  such  as:  genetic  background  speciﬁc  to  patients  with
M1;  association  of  abnormal  splicing  of  other  ion  channels
nvolved  in  myocardial  depolarization  or  repolarization;  and
peciﬁc  pattern  of  Nav1.5  isoforms  expression  differing  from
hat  observed  in  patients  with  SCN5A  gene  mutations.
ight ventricular myocardial tissue of a patient suffering from DM1
 exon 6A digestion) and ApoI (B) (red arrow indicates expression of
ls). C: control; DM1: dystrophia myotonica type 1; RT-PCR: reverse
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The  identiﬁcation  of  abnormal  splicing  of  SCN5A  and  our
linical  ﬁndings  raise  the  hypothesis  of  an  implication  of
odium  current  dysfunction  in  the  pathophysiology  of  car-
iac  involvement  in  DM1.  Aberrant  alternative  splicing  of
re-mRNAs  due  to  a  toxic  effect  of  mutant  DMPK  mRNAs
s  the  main  pathogenetic  characteristic  of  DM1  [3,4].  It
requently  leads  to  an  over-expression  of  foetal  splicing
soforms  which  have  been  related  to  disturbance  of  the
unctional  balance  between  splicing  regulators,  MBNL1  and
ELF1  [14,32].  In  our  study,  abnormal  splicing  of  SCN5A
xon  6  was  characterized  by  expression  of  a  foetal  iso-
orm  named  exon  6A.  The  deduced  protein  sequences  of
xon  6A  indicate  seven  amino  acid  exchanges,  resulting  in  a
reviously  reported  sodium  channel  variant  named  Nav1.5e
33],  expressed  at  the  embryonic  stage  of  development  in
everal  mammalian  species.  Nav1.5e  has  distinct  electro-
hysiological  properties,  resulting  in  a  sodium  current  loss
f  function,  including  depolarized  shift  of  steady-state  acti-
ation,  slower  kinetics  of  activation  and  inactivation,  slower
ecovery  from  inactivation  and  reduced  channel  availabil-
ty  compared  to  Nav1.5  [34].  The  hypothesis  of  a  link
etween  SCN5A  missplicing,  sodium  current  dysfunction  and
ardiac  manifestations  of  DM1  requires  validation  by  addi-
ional  studies.  However,  among  mRNAs  for  which  missplicing
as  been  identiﬁed  in  DM1  at  the  cardiac  level,  such  as
roponin  T,  SCN5A  is  the  only  one  that  could  potentially
ccount  for  several  manifestations  of  the  disease,  including
onduction  system  disease,  supraventricular  and  ventricu-
ar  arrhythmias  and  Brugada  pattern.  Furthermore,  clinical
anifestations  associated  with  mutations  in  the  SCN5A  gene
ausing  Na+  cardiac  channel  loss  of  function  [20,22]  are
ndeed  very  similar  to  those  observed  in  DM1  [5—8].
The  analysis  of  only  one  myocardial  sample  from  a  DM1
atient  with  terminal  heart  failure  represents  a  limitation
f  our  study.  Splicing  abnormalities  of  SCN5A  have  been
eported  in  patients  with  heart  failure,  but  were  different
rom  those  identiﬁed  in  our  patient,  mainly  at  the  terminal
egion  of  the  gene  [35].  We  could  not  conﬁrm  our  ﬁnd-
ngs  with  other  DM1  patient  samples  as  tissues  harvested
efore  death  are  extremely  rare  in  this  disease.  However,
he  relevance  of  our  ﬁndings  is  supported  by  the  absence  of
CN5A  exon  6  splicing  abnormalities  in  control  samples  of
atients  with  dilated  cardiomyopathy  and  the  identiﬁcation
f  an  over-expression  of  a  foetal  splicing  isoform,  which  is
 common  manifestation  of  DM1.
onclusions
ur  ﬁndings  suggest  a  high  prevalence  of  type  1  Brugada
attern  in  DM1  patients  and  may  generate  the  hypothesis
hat  abnormal  SCN5A  splicing  could  be  responsible  for  this
nding.
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